Safety and immunogenicity of GamEvac-Combi, a heterologous rVSV- and rAd5-vectored Ebola vaccine: a randomized controlled multicenter clinical trial in the Republic of Guinea and Russia
DY Logunov, Dolzhikova IV, MY Boiro, AV Kovyrshina, AS Dzharullaeva, AS Erokhova, DM Grousova, AI Tukhvatulin, FM Izhaeva, YV Simakova, MK Ordzhonikidze, NL Lubenets, OV Zubkova, DV Scheblyakov, IB Esmagambetov, MM Shmarov, AS Semikhin, NM Tukhvatulina, DN Shcherbinin, IL Tutykhina, GS Prokhorov, AA Khovaev, TN Demidova, NA Malishev, LN Merkulova, OL Voronina, IT Fedyakina, LB Kisteneva, LV Kolobukhina, DV Mishin, AL Elakov, EI Ermolova, KG Krasnoslobodtsev, VF Larichev, IS Kruzhkova, EM Burmistrov, AB Sheremet, EA Tokarskaya, AV Gromov, DA Reshetnikov, AY Fisun, BN Kotiv, DV Ovchinnikov, EV Ivchenko, KV Zhdanov, SM Zakharenko, AN Solovev, AM Ivanov, VS Sukachev, RV Gudkov, OV Maltsev, IA Gabdrahmanov, AV Barsukov, VV Vashchenkov, NY Demianenko, SB Ignatev, KV Asyamov, NN Kirichenko, AV Lyubimov, Volkov II, EV Kryukov, NK Bazarnov, V Kolodyazhnaya, EV Kolomoets, SI Syromyatnikova, DE Chifanov, AF Andrus, DA Kutaev, SV Borisevich, BS Naroditsky, AL Gintsburg, the GamEvac-Combi trial group
medRxiv 2024.08.21.24312344; doi: https://doi.org/10.1101/2024.08.21.24312344
